title: Immunochemotherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony.
abstract: The clinical, parasitological, hematological, and serological evolution of visceral leishmaniasis in Brazilian patients was assessed during treatment with human recombinant interferon-gamma (rIFN-gamma; 0.1 mg/m2 i.m. days 1-14) followed by pentavalent antimony (Sbv; 10 mg/kg days 22-28). At day 30, 6 patients had improved, 2 had slightly improved, and 1 patient had deteriorated. IFN-gamma was well tolerated in the dose tested and may be very effective as an adjunct to conventional therapy with antimony.
authors.affiliation: Landesinstitut für Tropenmedizin Berlin, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Harms
authors.forename: K
authors.initials: K
authors.lastname: Zwingenberger
authors.forename: B
authors.initials: B
authors.lastname: Sandkamp
authors.forename: S
authors.initials: S
authors.lastname: Omena
authors.forename: C
authors.initials: C
authors.lastname: Pedrosa
authors.forename: J
authors.initials: J
authors.lastname: Richter
authors.forename: F
authors.initials: F
authors.lastname: Rosenkaimer
authors.forename: H
authors.initials: H
authors.lastname: Feldmeier
authors.forename: U
authors.initials: U
authors.lastname: Bienzle
mesh_terms: D000293:Adolescent; D000328:Adult; D000965:Antimony / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D007898:Leishmaniasis, Visceral / Q000628:therapy*; D008297:Male; D010865:Pilot Projects; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D007371:Interferon-gamma; D000965:Antimony